For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for neuromyelitis ...

IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...

This study found that treatment with inebilizumab greatly reduced the symptoms of immunoglobulin G4–related disease (IgG4-RD), compared to placebo.

Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, ...

Immunoglobulin 4-related disease (IgG4-RD) is known for its potential to affect nearly every organ, particularly a preference for large and middle-sized arteries when vascular involvement occurs.

Ocular autoimmune disease involves the immune system attacking the tissues of the eye. These diseases typically manifest through an autoantibody response targeting the retina, uvea, vitreous, and ...

Dr. Stone said, "A crucial finding for people living with IgG4-RD now has been the efficacy in disease control exerted by B cell depletion. I'm enthusiastic now not only about the possibility of ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...